X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs NOVARTIS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA NOVARTIS GSK PHARMA/
NOVARTIS
 
P/E (TTM) x 62.9 360.9 17.4% View Chart
P/BV x 10.1 17.8 56.9% View Chart
Dividend Yield % 1.3 1.6 77.1%  

Financials

 GSK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
NOVARTIS
Mar-16
GSK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,838982 390.8%   
Low Rs2,637556 474.1%   
Sales per share (Unadj.) Rs354.2252.9 140.0%  
Earnings per share (Unadj.) Rs39.862.1 64.0%  
Cash flow per share (Unadj.) Rs42.963.3 67.7%  
Dividends per share (Unadj.) Rs30.0010.00 300.0%  
Dividend yield (eoy) %0.91.3 71.3%  
Book value per share (Unadj.) Rs236.9363.6 65.2%  
Shares outstanding (eoy) m84.7031.96 265.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.13.0 300.6%   
Avg P/E ratio x81.412.4 657.9%  
P/CF ratio (eoy) x75.512.2 621.5%  
Price / Book Value ratio x13.72.1 646.0%  
Dividend payout %75.416.1 468.8%   
Avg Mkt Cap Rs m274,21624,580 1,115.6%   
No. of employees `0004.70.8 624.6%   
Total wages/salary Rs m4,8301,801 268.2%   
Avg. sales/employee Rs Th6,387.010,748.9 59.4%   
Avg. wages/employee Rs Th1,028.32,395.2 42.9%   
Avg. net profit/employee Rs Th717.12,641.1 27.1%   
INCOME DATA
Net Sales Rs m30,0008,083 371.1%  
Other income Rs m728829 87.8%   
Total revenues Rs m30,7288,913 344.8%   
Gross profit Rs m4,190234 1,789.0%  
Depreciation Rs m26337 716.6%   
Interest Rs m02 0.0%   
Profit before tax Rs m4,6551,025 454.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m4571,696 26.9%   
Tax Rs m1,744752 231.9%   
Profit after tax Rs m3,3681,986 169.6%  
Gross profit margin %14.02.9 482.0%  
Effective tax rate %37.573.4 51.1%   
Net profit margin %11.224.6 45.7%  
BALANCE SHEET DATA
Current assets Rs m16,74212,678 132.1%   
Current liabilities Rs m7,2022,433 296.0%   
Net working cap to sales %31.8126.7 25.1%  
Current ratio x2.35.2 44.6%  
Inventory Days Days5233 158.5%  
Debtors Days Days2122 92.4%  
Net fixed assets Rs m8,63569 12,478.6%   
Share capital Rs m847160 530.0%   
"Free" reserves Rs m19,22211,460 167.7%   
Net worth Rs m20,06911,621 172.7%   
Long term debt Rs m100-   
Total assets Rs m30,03814,400 208.6%  
Interest coverage xNM570.5-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.6 177.9%   
Return on assets %11.213.8 81.2%  
Return on equity %16.817.1 98.2%  
Return on capital %25.523.6 108.0%  
Exports to sales %00.7 0.0%   
Imports to sales %018.6 0.0%   
Exports (fob) Rs mNA60 0.0%   
Imports (cif) Rs mNA1,503 0.0%   
Fx inflow Rs m528186 283.4%   
Fx outflow Rs m7,1931,821 395.0%   
Net fx Rs m-6,665-1,635 407.8%   
CASH FLOW
From Operations Rs m2,3602,531 93.2%  
From Investments Rs m3,008-8,270 -36.4%  
From Financial Activity Rs m-5,108-386 1,324.2%  
Net Cashflow Rs m260-6,125 -4.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 2.0 510.0%  
FIIs % 23.8 1.6 1,487.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.5 71.6%  
Shareholders   102,036 41,647 245.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - FDC LTD. COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS